Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 56.22 Billion KRW | -6.57% |
| 2022 | 60.18 Billion KRW | 18.25% |
| 2021 | 50.89 Billion KRW | 34.81% |
| 2020 | 37.75 Billion KRW | 16.22% |
| 2019 | 32.48 Billion KRW | 14.57% |
| 2018 | 28.35 Billion KRW | 12.52% |
| 2017 | 25.19 Billion KRW | -9.49% |
| 2016 | 27.83 Billion KRW | 10.58% |
| 2015 | 25.17 Billion KRW | 24.91% |
| 2014 | 20.15 Billion KRW | -39.66% |
| 2013 | 33.4 Billion KRW | 200.63% |
| 2012 | 11.11 Billion KRW | 8.07% |
| 2011 | 10.28 Billion KRW | 61.45% |
| 2010 | 6.36 Billion KRW | -11.4% |
| 2009 | 7.18 Billion KRW | -13.68% |
| 2008 | 8.32 Billion KRW | -32.09% |
| 2007 | 12.26 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 10.97 Billion KRW | -16.94% |
| 2024 Q2 | 17.81 Billion KRW | 62.31% |
| 2023 Q4 | 13.21 Billion KRW | 8.58% |
| 2023 FY | 56.22 Billion KRW | -6.57% |
| 2023 Q1 | 13.1 Billion KRW | 9.85% |
| 2023 Q2 | 17.74 Billion KRW | 35.38% |
| 2023 Q3 | 12.16 Billion KRW | -31.42% |
| 2022 Q1 | 17.41 Billion KRW | 47.66% |
| 2022 Q2 | 13.57 Billion KRW | -22.07% |
| 2022 Q4 | 11.93 Billion KRW | -30.87% |
| 2022 Q3 | 17.25 Billion KRW | 27.13% |
| 2022 FY | 60.18 Billion KRW | 18.25% |
| 2021 Q1 | 12.15 Billion KRW | 35.49% |
| 2021 Q3 | 13.17 Billion KRW | -4.29% |
| 2021 Q4 | 11.79 Billion KRW | -10.46% |
| 2021 Q2 | 13.76 Billion KRW | 13.24% |
| 2021 FY | 50.89 Billion KRW | 34.81% |
| 2020 FY | 37.75 Billion KRW | 16.22% |
| 2020 Q3 | 7.87 Billion KRW | -30.84% |
| 2020 Q2 | 11.39 Billion KRW | 19.78% |
| 2020 Q4 | 8.97 Billion KRW | 13.88% |
| 2020 Q1 | 9.51 Billion KRW | -6.14% |
| 2019 Q4 | 10.13 Billion KRW | 87.25% |
| 2019 FY | 32.48 Billion KRW | 14.57% |
| 2019 Q1 | 8.18 Billion KRW | -12.49% |
| 2019 Q2 | 8.75 Billion KRW | 7.05% |
| 2019 Q3 | 5.41 Billion KRW | -38.21% |
| 2018 FY | 28.35 Billion KRW | 12.52% |
| 2018 Q3 | 8.25 Billion KRW | 72.25% |
| 2018 Q2 | 4.79 Billion KRW | -19.45% |
| 2018 Q1 | 5.95 Billion KRW | -22.52% |
| 2018 Q4 | 9.34 Billion KRW | 13.21% |
| 2017 FY | 25.19 Billion KRW | -9.49% |
| 2017 Q2 | 6.94 Billion KRW | 25.67% |
| 2017 Q4 | 7.68 Billion KRW | 52.32% |
| 2017 Q3 | 5.04 Billion KRW | -27.4% |
| 2017 Q1 | 5.52 Billion KRW | -11.96% |
| 2016 Q1 | 7.07 Billion KRW | -7.35% |
| 2016 Q3 | 8.03 Billion KRW | 24.56% |
| 2016 FY | 27.83 Billion KRW | 10.58% |
| 2016 Q2 | 6.45 Billion KRW | -8.78% |
| 2016 Q4 | 6.27 Billion KRW | -21.88% |
| 2015 Q2 | 5.64 Billion KRW | 9.11% |
| 2015 Q4 | 7.63 Billion KRW | 13.51% |
| 2015 FY | 25.17 Billion KRW | 24.91% |
| 2015 Q1 | 5.17 Billion KRW | -10.96% |
| 2015 Q3 | 6.72 Billion KRW | 19.16% |
| 2014 Q3 | 4.91 Billion KRW | 34.84% |
| 2014 FY | 20.15 Billion KRW | -39.66% |
| 2014 Q4 | 5.8 Billion KRW | 18.16% |
| 2014 Q2 | 3.64 Billion KRW | -36.96% |
| 2014 Q1 | 5.78 Billion KRW | 43.06% |
| 2013 Q2 | 8.71 Billion KRW | -14.35% |
| 2013 FY | 33.4 Billion KRW | 200.63% |
| 2013 Q4 | 4.04 Billion KRW | -61.4% |
| 2013 Q3 | 10.47 Billion KRW | 20.17% |
| 2013 Q1 | 10.17 Billion KRW | 224.43% |
| 2012 Q2 | 3.06 Billion KRW | 49.73% |
| 2012 Q1 | 2.04 Billion KRW | 0.0% |
| 2012 FY | 11.11 Billion KRW | 8.07% |
| 2012 Q4 | 3.13 Billion KRW | 11.5% |
| 2012 Q3 | 2.81 Billion KRW | -8.1% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 10.28 Billion KRW | 61.45% |
| 2011 Q3 | 2.45 Billion KRW | -2.23% |
| 2011 Q1 | 1.81 Billion KRW | -8.58% |
| 2011 Q2 | 2.5 Billion KRW | 38.32% |
| 2010 Q2 | 1.42 Billion KRW | -5.15% |
| 2010 Q3 | 1.45 Billion KRW | 1.97% |
| 2010 Q4 | 1.98 Billion KRW | 36.47% |
| 2010 FY | 6.36 Billion KRW | -11.4% |
| 2010 Q1 | 1.5 Billion KRW | -42.84% |
| 2009 Q1 | 1.75 Billion KRW | -5.9% |
| 2009 Q2 | 1.76 Billion KRW | 0.27% |
| 2009 Q3 | 1.03 Billion KRW | -41.33% |
| 2009 Q4 | 2.63 Billion KRW | 154.22% |
| 2009 FY | 7.18 Billion KRW | -13.68% |
| 2008 Q1 | 2.61 Billion KRW | -34.71% |
| 2008 Q4 | 1.86 Billion KRW | 9.28% |
| 2008 Q3 | 1.71 Billion KRW | -19.95% |
| 2008 Q2 | 2.13 Billion KRW | -18.14% |
| 2008 FY | 8.32 Billion KRW | -32.09% |
| 2007 Q3 | 1.78 Billion KRW | -44.16% |
| 2007 Q1 | 3.27 Billion KRW | 0.0% |
| 2007 Q2 | 3.2 Billion KRW | -2.29% |
| 2007 FY | 12.26 Billion KRW | 0.0% |
| 2007 Q4 | 3.99 Billion KRW | 123.69% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -100.775% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | 97.268% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | 96.543% |
| Green Cross Corporation | 1626.64 Billion KRW | 96.543% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | -39.859% |
| Celltrion, Inc. | 2176.43 Billion KRW | 97.417% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 98.478% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | 84.783% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | 84.156% |
| Prestige BioPharma Limited | 689.07 Million KRW | -8059.834% |